Journal home
Advance online publication
Current issue
Archive
Press releases
Supplements
Focuses
Conferences
Guide to authors
Online submissionOnline submission
Permissions
For referees
Free online issue
Contact the journal
Subscribe
Advertising
work@npg
naturereprints
About this site
For librarians
 
NPG Resources
Bioentrepreneur
Nature Reviews Drug Discovery
Nature
Nature Medicine
Nature Genetics
Nature Reviews Genetics
Nature Methods
Nature Chemical Biology
news@nature.com
Clinical Pharmacology & Therapeutics
Nature Conferences
NPG Subject areas
Biotechnology
Cancer
Chemistry
Clinical Medicine
Dentistry
Development
Drug Discovery
Earth Sciences
Evolution & Ecology
Genetics
Immunology
Materials Science
Medical Research
Microbiology
Molecular Cell Biology
Neuroscience
Pharmacology
Physics
Browse all publications
Analysis
Nature Biotechnology 24, 531 - 536 (2006)
Published online: 5 May 2006; | doi:10.1038/nbt1195

In silico pharmacogenetics of warfarin metabolism

Yingying Guo1, Paul Weller2, Erin Farrell1, Paul Cheung2, Bill Fitch2, Douglas Clark2, Shao-yong Wu3, Jianmei Wang1, Guochun Liao1, Zhaomei Zhang1, John Allard1, Janet Cheng1, Anh Nguyen1, Sharon Jiang1, Steve Shafer4, Jonathan Usuka1, Mohammad Masjedizadeh3 & Gary Peltz1

1  Departments of Genetics and Genomics, Palo Alto S3-1, 3431 Hillview Ave., Palo Alto, California 94304, USA.

2  Drug Metabolism and Pharmacokinetics, Palo Alto S3-1, 3431 Hillview Ave., Palo Alto, California 94304, USA.

3  Chemical Services, Roche Palo Alto S3-1, 3431 Hillview Ave., Palo Alto, California 94304, USA.

4  Stanford University Department of Anesthesiology, Palo Alto, California 94305, USA.

Correspondence should be addressed to Gary Peltz gary.peltz@roche.com

Pharmacogenetic approaches can be instrumental for predicting individual differences in response to a therapeutic intervention. Here we used a recently developed murine haplotype-based computational method to identify a genetic factor regulating the metabolism of warfarin, a commonly prescribed anticoagulant with a narrow therapeutic index and a large variation in individual dosing. After quantification of warfarin and nine of its metabolites in plasma from 13 inbred mouse strains, we correlated strain-specific differences in 7-hydroxywarfarin accumulation with genetic variation within a chromosomal region encoding cytochrome P450 2C (Cyp2c) enzymes. This computational prediction was experimentally confirmed by showing that the rate-limiting step in biotransformation of warfarin to its 7-hydroxylated metabolite was inhibited by tolbutamide, a Cyp2c isoform-specific substrate, and that this transformation was mediated by expressed recombinant Cyp2c29. We show that genetic variants responsible for interindividual pharmacokinetic differences in drug metabolism can be identified by computational genetic analysis in mice.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Mycobacterial virulence and specialized secretion: same story, different ending

Nature Medicine News and Views (01 Mar 2007)

 Top
Abstract
Previous | Next
Table of contents
Full textFull text
Download PDFDownload PDF
Send to a friendSend to a friend
rights and permissionsRights and permissions
Order commercial reprintsOrder commercial reprints
CrossRef lists 6 articles citing this articleCrossRef lists 6 articles citing this article
Save this linkSave this link
Competing financial interests
Figures & Tables
Supplementary info
Export citation
natureproducts

Search buyers guide:

 
Nature Biotechnology
ISSN: 1087-0156
EISSN: 1546-1696
Journal home | Advance online publication | Current issue | Archive | Press releases | Supplements | Focuses | Conferences | For authors | Online submission | Permissions | For referees | Free online issue | About the journal | Contact the journal | Subscribe | Advertising | work@npg | naturereprints | About this site | For librarians
Nature Publishing Group, publisher of Nature, and other science journals and reference works©2006 Nature Publishing Group | Privacy policy